Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619852 | 0.69 | KDM4E (0.40) | ALDH1A1GAAALOX15MAPK1MEN1 | |
| SCHEMBL13619595 | 0.69 | ALDH1A1 (0.49) | ALDH1A1GAAMAPK1LMNAMEN1 | |
| SCHEMBL696762 | 0.65 | MAPK1 (0.54) | ALDH1A1GAAALOX15MAPK1LMNA | |
| SCHEMBL711780 | 0.65 | ALDH1A1 (0.65) | ALDH1A1GAAALOX15MAPK1LMNA | |
| SCHEMBL13857264 | 0.64 | MAPK1 (0.53) | ALDH1A1GAAALOX15MAPK1MEN1 | |
| SCHEMBL17438038 | 0.64 | ALDH1A1 (0.44) | ALDH1A1GAAALOX15MAPK1LMNA | |
| SCHEMBL10385396 | 0.63 | ALDH1A1 (0.58) | ALDH1A1GAAALOX15MAPK1LMNA | |
| SCHEMBL1583105 | 0.63 | ALDH1A1 (0.57) | ALDH1A1GAAALOX15MAPK1LMNA | |
| SCHEMBL696571 | 0.62 | MAPK1 (0.51) | ALDH1A1GAAALOX15MAPK1MEN1 | |
| SCHEMBL4272556 | 0.62 | GAA (0.71) | ALDH1A1GAAALOX15MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009134616-A2 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | INTERMUNE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257979-A1 | Novel Inhibitors of Hepatitis C Virus Replication | EIF2AK2, HAVCR2, HDGF | ALDH1A1 1614/4885GAA 799/4885ALOX15 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.